Engineered immune cells take on lupus in early trial
NCT ID NCT06585514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called CD19 CAR T cells for people with severe lupus that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack faulty immune cells driving the disease. The trial aims to see if it is safe and can reduce lupus symptoms, but patients may still need ongoing medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new antibody tame lupus flares?
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Blood traps may reveal lupus kidney treatment success
- A simple blood marker may reveal hidden heart risks in lupus
- Can a gentler steroid dose protect children's kidneys without the harsh side effects?